Andrew Xuan

Mar 5, 2023 | accpjournals.onlinelibrary.wiley.com | Jeromie Ballreich |Mariana P. Socal |Charles Bennett |Andrew Xuan

RESEARCH ARTICLE This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1002/phar.2789. Abstract INTRODUCTION The accelerated approval pathway allows for drug approval based on surrogate outcome measures “reasonably likely” to predict clinical benefit.